Monitor the June 30 shareholder meeting for approval of Series warrants, which would trigger additional dilution if exercised. The accelerated closing may indicate near-term cash needs, but no new financial details are provided in this filing.
Price Chart
Executive Summary
Akari Therapeutics amended its securities purchase agreement to consolidate the second and third closings into a single combined closing on June 26, 2026, issuing the remaining 980,395 ADSs (or prefunded warrants). Delivery of Series H, I, and J warrants is contingent on shareholder approval at the June 30 annual general meeting. This is an administrative acceleration of previously disclosed financing, not a new event.
Key Facts
- Amendment consolidates second and third closings into one combined closing on June 26, 2026.
- Remaining 980,395 ADSs (or prefunded warrants) issued at the combined closing.
- Series H, I, and J warrants delivery contingent on shareholder approval at AGM on June 30, 2026.
- Original offering was for 1,470,588 ADSs plus warrants; first closing occurred May 27, 2026.
Financial Impact
Undisclosed amount - see prior 8-K for gross proceeds; remaining 980,395 ADSs issued at combined closing.
Risk Factors
- Dilution from issuance of 980,395 ADSs (each representing 80,000 ordinary shares).
- Shareholder approval required for Series warrants; failure could limit future warrant exercises.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-030341 |
| Exhibit: ex10-1.htm | 0001493152-26-030341 |
| Document: 0001493152-26-030341-index-headers.html | 0001493152-26-030341 |
| Document: 0001493152-26-030341-index.html | 0001493152-26-030341 |
| Document: 0001493152-26-030341.txt | 0001493152-26-030341 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 24d ago | DEF 14A | $8.72 | awaiting T+60 | — | $7.82 (−10.32%) |
Oct 1, 2026 24d ago | 8-K | $8.72 | awaiting T+60 | — | $7.82 (−10.32%) |
Aug 13, 2026 10w ago | 8-K | $7.54 | awaiting T+60 | — | $7.82 (+3.71%) |
Jul 14, 2026 14w ago | EFFECT | $13.42 $8.63 | ▲ +35.73% | ▲ +39.11% | $7.82 (+41.73%) |
Jul 8, 2026 15w ago | EFFECT | $14.21 $8.84 | ▼ −37.79% | ▼ −40.28% | $7.82 (−44.97%) |
Jul 2, 2026 16w ago | S-3 | $10.41 $9.81 | ▲ +5.76% | ▲ +9.33% | $7.82 (+24.88%) |
Jun 29, 2026 17w ago | Press Release | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $7.82 (−19.30%) |
Jun 26, 2026 17w ago | 8-K | $9.69 $10.05 | ▲ +3.72% | ▼ −0.67% | $7.82 (−19.30%) |
May 28, 2026 21w ago | Press Release | $22.05 $7.85 | ▼ −64.40% | ▼ −66.13% | $7.82 (−64.54%) |
May 22, 2026 22w ago | 8-K | $17.81 $7.90 | ▲ +55.64% | ▲ +58.37% | $7.82 (+56.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers